Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Retained Earnings: 2017-2024

Historic Retained Earnings for Arcus Biosciences (RCUS) over the last 8 years, with Dec 2024 value amounting to -$1.1 billion.

  • Arcus Biosciences' Retained Earnings fell 32.85% to -$1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.4 billion, marking a year-over-year decrease of 32.85%. This contributed to the annual value of -$1.1 billion for FY2024, which is 33.33% down from last year.
  • According to the latest figures from FY2024, Arcus Biosciences' Retained Earnings is -$1.1 billion, which was down 33.33% from -$849.0 million recorded in FY2023.
  • In the past 5 years, Arcus Biosciences' Retained Earnings ranged from a high of -$275.0 million in FY2021 and a low of -$1.1 billion during FY2024.
  • Its 3-year average for Retained Earnings is -$841.0 million, with a median of -$849.0 million in 2023.
  • In the last 5 years, Arcus Biosciences' Retained Earnings increased by 16.21% in 2021 and then crashed by 97.09% in 2022.
  • Over the past 5 years, Arcus Biosciences' Retained Earnings (Yearly) stood at -$328.2 million in 2020, then grew by 16.21% to -$275.0 million in 2021, then slumped by 97.09% to -$542.0 million in 2022, then slumped by 56.64% to -$849.0 million in 2023, then tumbled by 33.33% to -$1.1 billion in 2024.